The largest database of trusted experimental protocols
> Disorders > Mental or Behavioral Dysfunction > Affective Disorders, Psychotic

Affective Disorders, Psychotic

Affective Disorders, Psychotic: A group of mental health conditions characterized by a combination of emotional and psychotic symptoms.
These disorders may involve disturbances in mood, perception, cognition, and behavior, impacting an individual's ability to function effectively.
Affective Disorders, Psychotic encompass a range of conditions, such as schizoaffective disorder, bipolar disorder with psychotic features, and major depressive disorder with psychotic features.
Effective management often requires a multifaceted approach, including pharmacological interventions, psychotherapy, and supportive care.
Reasearchers continue to explore the underlying mechanisms and develop novel therapies to improve outcomes for individuals affected by these complex and challenging disorders.

Most cited protocols related to «Affective Disorders, Psychotic»

The HADS includes data from 38 Army/DoD administrative data systems.26 (link) (See eTable 2 at http://www.armystarrs.org/publications) Troister et al.,27 (link) in a comprehensive review of 8 published studies of predictors of civilian post-hospital suicides, found five replicated classes of predictors: (i) socio-demographics (the most consistent being male gender and recent job loss); (ii) history of prior suicidal behaviors; (iii) quality of care (e.g., low continuity of care); (iv) time since hospital discharge (inversely related to suicide risk); and (v) other psychopathological risk factors (the most consistent being non-affective psychosis, mood disorders, and multiple comorbid psychiatric disorders). More recent studies found similar predictors.17 (link),28 (link),29 (link) We extracted HADS variables operationalizing these predictors and added Army career variables found to predict military suicides,19 (link)–22 (link) unit variables, criminal justice variables (violent crime victimization-perpetration), and measures of registered weapons. Importantly, all predictors other than those involving the hospitalization were defined as of the month before hospitalization, while predicted suicides were in the 12 months after hospital discharge.
We cast a wide net in extracting HADS measures of the predictor constructs. For example, we distinguished 23 categories of psychiatric diagnoses defined largely by aggregated ICD-9-CM codes (e.g., ADHD/learning disorders [ICD-9-CM 314.0-315.9]), 8 additional categories of behavioral stressors (e.g., marital problems, other stressors/adversities, suicidal ideation and self-damaging behavior), and summary measures of any prior admission diagnoses, admission count variables, and parallel outpatient variables (eTable 1 at http://www.armystarrs.org/publications).We also included NDC psychotropic medication codes collapsed into 15 categories (e.g., antianxiety antidepressant, antipsychotic) and 25 sub-categories (e.g., SSRI, SNRI, TCA) based on the First Databank (FDB) Enhanced Therapeutic Classification System™ (http://www.fdbhealth.com) (eTable 3 at http://www.armystarrs.org/publications). A total of 421 individual variables were constructed (eTable 4 at http://www.armystarrs.org/publications).
As the HADS data systems were not developed for research, there was more missing-inconsistent data in some (e.g., socio-demographic) component datasets than in research datasets. However, as HADS datasets are updated monthly, missing values typically appeared in earlier and/or later months, allowing nearest neighbor imputations. Remaining missing values were resolved using randomly selected multiple imputations.30 Inconsistencies were reconciled using rational imputations (e.g., a soldier classified female one month but male others was recoded male).
Publication 2014
4-amino-4'-hydroxylaminodiphenylsulfone Affective Disorders, Psychotic Antidepressive Agents Antipsychotic Agents CD3EAP protein, human Continuity of Patient Care Diagnosis Diagnosis, Psychiatric Disorder, Attention Deficit-Hyperactivity Hospitalization Learning Disorders Males Mental Disorders Military Personnel Mood Disorders Outpatients Patient Discharge Psychotropic Drugs Quality of Health Care SNRIs Soldiers Therapeutics Victimization Woman
404 individuals between ages 15-40 were enrolled. (a consort diagram appears in Supplemental Figure S1.) DSM-IV (18 ) diagnoses of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder not otherwise specified were included. Diagnoses of affective psychosis, substance-induced psychotic disorder, psychosis due to general medical conditions, clinically significant head trauma, or other serious medical conditions were excluded. All participants had experienced only one episode of psychosis (i.e. individuals with a psychotic episode followed by full symptom remission and relapse to another psychotic episode were excluded) and had taken ≤6 months of lifetime antipsychotics. All spoke English.
Written informed consent was obtained from adult participants and legal guardians of those under 18 years old, who provided written assent. The study was approved by the Institutional Review Boards of the coordinating center and the participating sites. The NIMH Data and Safety Monitoring Board provided study oversight.
Publication 2015
Adult Affective Disorders, Psychotic Antipsychotic Agents Clinical Trials Data Monitoring Committees Craniocerebral Trauma Diagnosis Ethics Committees, Research Legal Guardians Mental Disorders Psychoses, Substance-Induced Psychosis, Brief Reactive Psychotic Disorders Relapse Schizoaffective Disorder Schizophrenia Schizophreniform Disorders

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
Affective Disorders, Psychotic Birth Childbirth Diagnosis Differential Diagnosis Hypersensitivity Inpatient Outpatients Patients Regional Ethics Committees Schizophrenia Seizures
We report on clinical and demographic characteristics of patients enrolled in OnTrack during the first 2.5 years. We provide data on all patients seen in the clinic, as well as those actively receiving treatment in OnTrack as of January 21, 2015. We considered a patient to be active if they received any component of treatment at OnTrack within the prior three months.
We also explore clinical and demographic characteristics by category of psychosis [affective psychosis, primary psychotic disorder, psychotic disorder not otherwise specified (NOS), and no psychosis], providing age, duration of treatment in the program, referral source, hospitalization history, history of pre-morbid substance use disorders (SUD), and pre-morbid functional status (whether a patient was working or attending school prior to program entry). Patients were categorized on the basis of their current diagnoses as of January 21, 2015, extracted from OnTrack medical records. Lastly, we report on the initial referral diagnoses and the evolution of provisional diagnoses during treatment. We obtained referral diagnoses from medical records and intake paperwork completed by referring clinicians and/or family members.
Publication 2015
Affective Disorders, Psychotic Biological Evolution Diagnosis Family Member Hospitalization Patients Psychotic Disorders Substance Use Disorders Vision
The early detection strategy (ED) will target all residents of a designated geographic catchment contiguous with the Connecticut Mental Health Center (CMHC) in which STEP is located. This includes the 8 towns of Bethany, Orange, Woodbridge, Hamden, New Haven, East Haven, West Haven and North Haven, with a total population of 323,285 (Census, 2010) and for which we estimate an annual incidence 40–70 cases of schizophrenia-spectrum disorders. The catchment was chosen based on feasibility of travel for care at STEP. The intensive approach to ascertainment of new onset cases from across the catchment will include public messaging and targeted outreach to all major treatment centers. Also measurement of DUP will be undertaken at one other major community mental health center that draws from this catchment zone. At this community ‘sentinel’ site, in addition to the usual outreach, clinical records will be reviewed on a regular basis to determine the prognostic profile and DUP of patients who were not successfully referred to STEP for initiation of treatment. The control site, PREPR is based in the Jamaica Plains area of Boston and while it draws from a much larger metropolitan population of more than 4 million (Census 2010), the demographic and prognostic profile of usual recruits over the past 5 years have been broadly comparable to that of STEP (see section Choice of Control site below).
The focus of early intervention after the onset of a psychosis is to improve the outcomes of individuals with schizophrenia-spectrum disorders. The reality, embraced by all exemplar early intervention programs, is that an accurate diagnosis is often difficult to make at the time of symptom onset [42 (link)]. Thus a ‘first-episode’ psychosis sample will necessarily include patients who will, on longitudinal follow-up, turn out to have less severe illnesses such as major depression with psychotic features, brief psychotic disorder or bipolar disorder (with psychotic features). The study population is thus expected to be diagnostically heterogeneous in the service of identifying, with as much sensitivity as possible, those who are likely to develop chronic psychotic illnesses.
We will thus use criteria that are simple to communicate and apply, to minimize delays in determining eligibility:

Inclusion Criteria: 16–35 years old, must live within catchment of interest (For PREPR: greater Boston metropolitan area; for STEP: 8 town catchment) and must have had their first-episode of psychosis within the past 3 years.

Exclusion Criteria: Established diagnosis of Affective psychosis (i.e. non-ambiguous Bipolar d/o or MDD with psychotic features) or Psychosis secondary to substance use or a medical illness, unable to communicate in English, eligible for DDS (Department of Developmental Services), legally mandated to enter treatment, unable to reliably determine DUP, unstable serious medical illness. We will exclude from this study, those patients who converted to psychosis while being followed and cared for in prodromal clinics (i.e. DUP of 0), which exist at both sites. We will also exclude those who have previously received care at another FES.

Reasons for exclusion and patient refusal will be recorded for all referrals. DUP will be estimated for refusers who are otherwise eligible, to gauge the impact of sampling bias on the relationship between DUP reduction and early outcomes.
Written informed consent for participation in the study will be obtained from all adult participants. For those participants under 18 years of age, written consent will be obtained from a parent or legal guardian in addition to written assent from the participant. All procedures are in compliance with the Helsinki Declaration and have received ethics approval from the Yale University Human Investigation Committee (Protocol Number: 1310012846).
Full text: Click here
Publication 2014
Adult Affective Disorders, Psychotic Bipolar Disorder Diagnosis Disease, Chronic Early Diagnosis Early Intervention (Education) Eligibility Determination Ethics Committees Genetic Heterogeneity Homo sapiens Hypersensitivity Legal Guardians Mental Disorders Mental Health Parent Patients Psychosis, Brief Reactive Psychotic Disorders Schizophrenia Substance Use

Most recents protocols related to «Affective Disorders, Psychotic»

Classic mental health disorder is defined as a lifetime history of any of the following 22 diagnoses as indicated by administrative ICD‐9 codes: ADHD, adjustment disorder, alcohol, anxiety, bipolar, conduct/ODD, minor depression, MDD, eating disorders, non‐affective psychosis, organic mental disorders, other disorders, other impulse‐control disorders, personality disorders, sex disorders, sleep disorders, somatoform/dissociative disorders, traumatic stress, PTSD, drug‐induced mental illness, drug abuse without dependence, or drug dependence.
Publication 2023
Adjustment Disorders Affective Disorders, Psychotic Anxiety Disorders Delirium, Dementia, Amnestic, Cognitive Disorders Diagnosis Disorder, Attention Deficit-Hyperactivity Disorder, Dissociative Disruptive, Impulse Control, and Conduct Disorders Drug Abuse Drug Dependence Eating Disorders Ethanol Mental Disorders Personality Disorders Pharmaceutical Preparations Physiological Sexual Disorders Post-Traumatic Stress Disorder Sleep Disorders
Psychotic experiences were assessed with the Prodromal Questionnaire Brief Version [24 (link)] (PQ-B) and the Kiddie Schedule for Affective Disorders and Schizophrenia [25 ] (KSADS-5). The PQ-B is a 21-item child-report questionnaire designed to measure the presence and severity of psychotic-like experiences (PLEs) in childhood. PQ-B symptom scores (PQ-Bsym) were calculated as the total number of endorsed PLEs; severity score (PQ-Bsev) was calculated as the child-reported level of distress (range 1–5) across all endorsed items. In line with previous research indicating that unusual thought content and suspiciousness are most predictive of psychosis risk [26 ], a binary score (PPbin) was developed by defining prodromal psychosis “cases” as youth who endorsed experiencing at least 3 PLEs reflecting suspicious or unusual thought content (i.e., PQ-B items 1, 4, 5, 7, 8, 11, 12, 13–18), significant distress related to these experiences (i.e., PQ-B distress scores > 6 across items 1, 4, 5, 7, 8, 11, 12, 13–18), and whose parents indicated the child experienced hallucinations, delusions, and associated psychotic symptoms on the KSADS-5 assessment; youth not meeting these criteria served as the “control” group. Cognitive and psychiatric variables from the reported C4 phenome-wide association study (PheWAS) can be found in Additional file 1: Table S3.
Rates and severity of childhood PLEs were non-normally distributed, with the majority of youth reporting zero or few PLE symptoms (PQ-Bsym; M = 2.55, SD = 3.52) and endorsing low levels of PLE severity (PQ-Bsev; M = 6.09, SD = 10.39; Fig. 1B).
Full text: Click here
Publication 2023
Affective Disorders, Psychotic Child Cognition Delusions Hallucinations Mental Disorders Parent Prodromal Symptoms Psychotic Disorders Schizophrenia Youth
Inclusion criteria. Participants: Staff facilitating the self-management intervention in a secondary mental health service, or people with a clinical diagnosis of non-affective psychosis (schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, psychotic disorder not otherwise defined), bipolar disorder, or major depression who are receiving the intervention.
Interventions: The criteria used to define supported self-management were as in a previous review of effectiveness of supported self-management interventions conducted by members of the same research group [7 (link)]. To be included in the review, the intervention was required to include all of the following three domains, which are three of four domains that Mueser and colleagues [6 (link)] described as “effective areas of self-management”:
Comparator(s)/control: A comparator or control group was not required.
Exposures: Any primary data on factors which influence the implementation of self-management interventions for people with SMI in secondary mental health services.
Design: Full-text journal articles with primary qualitative or quantitative data (or both). If the primary focus of the study was not an investigation of the barriers or facilitators to the use of self-management interventions but the results section included data relevant to the research question, the study was included.
Full text: Click here
Publication 2023
Affective Disorders, Psychotic Bipolar Disorder Diagnosis Disorder, Delusional Major Depressive Disorder Mental Health Services Psychotic Disorders Schizoaffective Disorder Schizophrenia Schizophreniform Disorders Self-Management
We constructed a population-based retrospective cohort study to determine whether patients with mood disorders are more susceptible to developing cervical cancer. The mood-disorder cohort included women aged above 18 years who received a diagnosis of mood disorders (depression and bipolar) with at least two outpatient visits or at least one hospitalization record from 2000 to 2012 (Figure 1). Participants in the non-mood-disorder cohort were defined as participants without mood disorders. The diagnostic codes for mood disorders used to identify patients in this study are listed below. For depressive disorder, we used ICD-9-CM code 296.2 (major depressive disorder single episode), code 296.3 (major depressive disorder recurrent episode), code 300.4 (dysthymic disorder), and code 311 (depressive disorder, not elsewhere classified). For bipolar disorder, we used code 296.0 (manic disorder, single manic episode), code 296.1 (manic disorder, recurrent episode), code 296.4 (bipolar I disorder, most recent episode (or current) manic), code 296.5 (bipolar I disorder, most recent episode (or current) depressed), code 296.6 (bipolar I disorder, most recent episode (or current) mixed), code 296.7 (bipolar I disorder, most recent episode (or current) unspecified), code 296.8 (other affective psychoses), code 296.80 (bipolar disorder, unspecified), and code 296.89 (bipolar II disorder). The date of the first diagnosis of mood disorders was defined as the index date. Women aged above 18 years who had never received a diagnosis of mood disorders during the study period were randomly selected as the comparison cohort and propensity-matched with the mood-disorder cohort at a 4:1 ratio according to age and index year. We excluded participants with a history of any cancer (ICD-9-CM 140-208) before the index date. The main outcome was a new diagnosis of cervical cancer (ICD-9-CM 180.9 and 233.1) during the follow-up period. All participants in this study were followed from the index date until being diagnosed with cervical cancer and censored because of the loss to follow-up, withdrawal from insurance, or at the end of 2013. Baseline comorbidities before the index date including diabetes mellitus (ICD-9-CM 250), hypertension (ICD-9-CM 401-40 and A26), hyperlipidemia (ICD-9-CM 272), cardiovascular disease (ICD-9-CM 402, 410-414, 420-429, 430-438), chronic kidney disease (ICD-9-CM 580-589, A350), dementia (ICD-9-CM 290 and 294), and sexually transmitted diseases (ICD-9-CM 042, 054.1, 078.11, 091-098, 099.5 and 131) were investigated in this study. We also considered utilization of Pap smears in this study, and Pap smear density was calculated as the number of Pap smears per year during the follow-up period. The participants’ demographic characteristics were collected from both cohorts including age, urbanization level, employment category, and the follow-up duration.
Full text: Click here
Publication 2023
Affective Disorders, Psychotic Bipolar Disorder Bipolar Disorder Type 2 Cardiovascular Diseases Cervical Cancer Chronic Kidney Diseases Dementia Diabetes Mellitus Disorder, Depressive Dysthymic Disorder High Blood Pressures Hospitalization Hyperlipidemia Major Depressive Disorder Malignant Neoplasms Mania Manic Disorder Manic Episode Mood Disorders Outpatients Patients Sexually Transmitted Diseases Urbanization Vaginal Smears Woman
In the LHID 2000, there were 953,189 subjects had never been diagnosed with thalassemia from 1997 to 2013. Subsequently, we matched thalassemia patients with non-thalassemia individuals at a ratio of 1:4 by gender and age, there were 13,020 non-thalassemia individuals, who had the same index date with matched thalassemia patient and they were all at risk on the index date.To minimize the influence of confounding bias, we used a propensity score matching (PSM) to balance the baseline co-variate between study groups.The propensity score of patients with thalassemia was calculated by logistic regression using PROC PSMATCH under SAS software. Each thalassemia patient was 1:2 matched with individuals without thalassemia by the propensity score calculated using demographics (including age, sex, urbanization, insured unit), length of hospital stay, and co-morbidities (including rheumatoid arthritis, Sjogren’s syndrome, systemic sclerosis, vasculitis, hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, osteoporosis, stroke, asthma, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver diseases, hyperthyroidism, thyroiditis, pancreatitis, affective psychosis, ankylosing spondylitis, inflammatory bowel disease, human immunodeficiency virus infection, and antiphospholipid antibody syndrome) at baseline by the nested greedy algorithm with the caliper of 0.01. As a result, PSM identified 3126 thalassemia patients and 5766 non-thalassemia patients (Fig. 1).
Full text: Click here
Publication 2023
Affective Disorders, Psychotic Ankylosing Spondylitis Antiphospholipid Syndrome Asthma Cerebrovascular Accident Chronic Kidney Diseases Chronic Obstructive Airway Disease Coronary Artery Disease Diabetes Mellitus Disease, Chronic High Blood Pressures HIV Infections Hyperlipidemia Hyperthyroidism Inflammatory Bowel Diseases Liver Liver Diseases Osteoporosis Pancreatitis Patients Rheumatoid Arthritis Sjogren's Syndrome Systemic Scleroderma Thalassemia Thyroiditis Urbanization Vasculitis

Top products related to «Affective Disorders, Psychotic»

Sourced in United States, United Kingdom, Denmark, Belgium, Spain, Canada, Austria
Stata 12.0 is a comprehensive statistical software package designed for data analysis, management, and visualization. It provides a wide range of statistical tools and techniques to assist researchers, analysts, and professionals in various fields. Stata 12.0 offers capabilities for tasks such as data manipulation, regression analysis, time-series analysis, and more. The software is available for multiple operating systems.
Sourced in United States, United Kingdom, Germany
SPSS Statistics for Windows, Version 20.0 is a software application for statistical analysis. It provides tools for data management, visualization, and advanced statistical modeling. The software is designed to work on the Windows operating system.
Sourced in Germany
The Tim Trio MRI scanner is a magnetic resonance imaging (MRI) system developed by Siemens. It is designed to provide high-quality imaging of the human body for medical diagnostic purposes. The core function of the Tim Trio MRI scanner is to generate detailed images of internal structures and organs using strong magnetic fields and radio waves, allowing healthcare professionals to assess and diagnose various medical conditions.
Sourced in United States, Cameroon, Canada, Austria, Japan, Germany
SAS Enterprise Guide 7.1 is a point-and-click software application that provides a graphical user interface to the SAS System. It enables users to access, manage, and analyze data, as well as generate reports and visualizations, without requiring extensive programming knowledge.
Sourced in United States, Japan, Austria, Germany, United Kingdom, France, Cameroon, Denmark, Israel, Sweden, Belgium, Italy, China, New Zealand, India, Brazil, Canada
SAS software is a comprehensive analytical platform designed for data management, statistical analysis, and business intelligence. It provides a suite of tools and applications for collecting, processing, analyzing, and visualizing data from various sources. SAS software is widely used across industries for its robust data handling capabilities, advanced statistical modeling, and reporting functionalities.
Sourced in United States, United Kingdom, Germany, Canada, Japan, Sweden, Austria, Morocco, Switzerland, Australia, Belgium, Italy, Netherlands, China, France, Denmark, Norway, Hungary, Malaysia, Israel, Finland, Spain
MATLAB is a high-performance programming language and numerical computing environment used for scientific and engineering calculations, data analysis, and visualization. It provides a comprehensive set of tools for solving complex mathematical and computational problems.
Sourced in United States, United Kingdom, Spain, China, Germany, Austria
SPSS v26 is a statistical software package developed by IBM. It provides data management, analytical, and visualization capabilities to enable users to identify patterns, trends, and relationships within data sets.
Sourced in United States, Denmark, Austria, United Kingdom
Stata version 13 is a software package designed for data analysis, statistical modeling, and visualization. It provides a comprehensive set of tools for managing, analyzing, and presenting data. Stata 13 offers a wide range of statistical methods, including regression analysis, time-series analysis, and multilevel modeling, among others. The software is suitable for use in various fields, such as economics, social sciences, and medical research.
The Diagnostic test calculator is a software tool that enables healthcare professionals to quickly and accurately calculate the performance characteristics of diagnostic tests, such as sensitivity, specificity, positive and negative predictive values. The calculator facilitates evidence-based decision-making and supports the interpretation of test results.

More about "Affective Disorders, Psychotic"